Saudi SFDA News

SFDA grants orphan drug designation to Sephience for HPA/PKU

SFDA grants orphan drug designation to Sephience for HPA/PKU

SFDA CEO Discusses AI's Role in Drug Development and Regulatory Efficiency

The CEO of the Saudi SFDA highlighted the significant contributions of Artificial Intelligence (AI) to accelerating drug development, reducing costs, and enhancing regulatory efficiency for medicines, medical devices, and food products. The SFDA has launched an AI laboratory and developed a digital twin to integrate emerging innovations and streamline approval processes.

SFDA Grants Orphan Drug Designation to Agamree for Duchenne Muscular Dystrophy

The Saudi Food and Drug Authority (SFDA) has granted Santhera Pharmaceuticals orphan drug designation for Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD). This designation allows for a dedicated regulatory pathway for serious or rare diseases but does not constitute formal product registration.

SFDA Grants Breakthrough Designation to Bemlayo for Obesity/Overweight

The Saudi Food and Drug Authority (SFDA) has granted Eli Lilly's drug Bemlayo (Orforglipron) Breakthrough designation. This designation expedites the review process for innovative treatments for serious diseases but does not constitute marketing authorization.

SFDA CEO Congratulates Saudi Leadership on Eid al-Fitr

The CEO of the Saudi Food and Drug Authority (SFDA) extended Eid al-Fitr greetings to the Saudi leadership and people. The announcement also highlighted the SFDA's role in ensuring the safety of food, medicine, and medical devices during the Umrah season.